Not directly related to TLT but using light therapy with gold nanorods in the fight against cancer.
Thought some might be interested in the story.
Sona Nanotech files patent application for photothermal light device
- Sona Nanotech (CSE:SONA) has submitted a provisional patent application with the U.S. Patent and Trademark Office for its proprietary photothermal light device
- A prototype of the company’s medical laser was engineered in tandem with Minnetronix Medical to apply non-thermal, 860 nanometre wavelength high-intensity infrared laser light
- The company also recently met with a group of surgeons and payer representatives in the U.S as part of its second EXCITE International panel discussion
- Shares of Sona Nanotech are up 19.05 per cent to C$0.50 as of 11:48 am ET.
Sona Nanotech (CSE:SONA) has revealed it has submitted a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its proprietary photothermal light device.
In a news release, the company stated that a prototype of its medical laser was engineered in tandem with Minnetronix Medical to apply non-thermal, 860 nanometer wavelength high-intensity infrared laser light.
The device was designed to be used with Sona’s patent pending biocompatible gold nanorods, which has proven to convert the non-thermal light energy into heat. The device has controls to regulate the intensity and duration of the light exposure and to permit a user to monitor and control the temperature generated in tissue.
The Halifax, Nova Scotia-based company also revealed its application to the USPTO, titled “Endoscope with EMR Optical Fibre and Thermal Sensor for Photothermal Therapy,” comes in tandem with a recent pre-submission meeting with the U.S. Food and Drug Administration (FDA).
“Sona’s recent roundtable session with its panel of surgeons from leading U.S. academic medical centres and medical payment organizations provided us with invaluable counsel on considerations for both the ‘indications for use’ for Sona’s targeted hyperthermia therapy and the research data that may be required to secure payment codes from payers,” David Regan, CEO of Sona Nanotech, said in a statement. “This guidance, together with recent feedback received from the FDA, gives us confidence in the appropriateness of our research study pathway and the likelihood of acceptance by physicians and healthcare institutions of our cancer treatment.
The company said its targeted hyperthermia therapy cancer therapy device is being used for Sona Nanotech’s ongoing pre-clinical efficacy study of its targeted hyperthermia therapy cancer treatment at Dalhousie University.
Sona Nanotech is focused on the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications.